Cargando…
Plasma Exosomes Transfer miR-885-3p Targeting the AKT/NFκB Signaling Pathway to Improve the Sensitivity of Intravenous Glucocorticoid Therapy Against Graves Ophthalmopathy
Graves ophthalmopathy (GO), a manifestation of Graves’ disease, is an organ-specific autoimmune disease. Intravenous glucocorticoid therapy (ivGCs) is the first-line treatment for moderate-to-severe and active GO. However, ivGCs is only effective in 70%–80% of GO patients. Insensitive patients who c...
Autores principales: | Sun, Jingxue, Wei, Jiaxing, Zhang, Yaguang, Li, Jingjing, Li, Jian, Yan, Jiazhuo, Guo, Min, Han, Jun, Qiao, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900193/ https://www.ncbi.nlm.nih.gov/pubmed/35265076 http://dx.doi.org/10.3389/fimmu.2022.819680 |
Ejemplares similares
-
Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients
por: Ahn, Hwa Young, et al.
Publicado: (2020) -
Exploring the Role of SRC in Extraocular Muscle Fibrosis of the Graves’ Ophthalmopathy
por: Hao, Mingyu, et al.
Publicado: (2020) -
Tear-derived exosomal biomarkers of Graves’ ophthalmopathy
por: Shi, Ting-Ting, et al.
Publicado: (2022) -
Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves' Ophthalmopathy: A Meta-Analysis
por: Chen, Jing, et al.
Publicado: (2021) -
Autophagy in graves’ ophthalmopathy
por: Chen, Yu-Qing, et al.
Publicado: (2023)